Opendata, web and dolomites

PICSOHF SIGNED

PICSOHF, A minimally invasive cardiac intervention medical device to regenerate a damaged heart and extend the life of patients with Heart Failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PICSOHF project word cloud

Explore the words cloud of the PICSOHF project. It provides you a very rough idea of what is the project "PICSOHF" about.

minutes    sustainability    patients    controls    worldwide    regeneration    improvements    pattern    hope    catheter    software    reference    miracor    ed    full    clinical    quality    scientific    tested    innate    treating    elevates    right    consists    morbidities    demonstrated    partial    changing    picso    burden    26    intervention    commercial    biomarkers    profits    greatest    proof    device    therapies    healthcare    66m    discredited    survival    follow    solutions    tissue    reactivating    cellular    attack    live    market    impoverished    cardiac    threatens    hospitalisations    patented    life    therapy    chronic    stop    continuous    unable    hf    europe    people    versus    clinically    regenerate    progressive    co    veins    picsohf    medium    22    acute    function    expectations    breakthrough    million    regain    prognosis    strategic    recovery    launch    temporarily    met    frequent    despite    patient    feedback    changed    last    technological    expectancy    damaged    pressure    percutaneous    proprietary    efficacy    regenerative    national    treatments    once    treatment    significantly    heart    re    myocardial   

Project "PICSOHF" data sheet

The following table provides information about the project.

Coordinator
MIRACOR MEDICAL 

Organization address
address: RUE DE BRUXELLES 174, E40 BUSINESS
city: AWANS
postcode: 4340
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MIRACOR MEDICAL BE (AWANS) coordinator 50˙000.00

Map

 Project objective

Worldwide 26 million people live with HF (Heart Failure) which is a major burden, not only for the patient, but one that also threatens the sustainability of national healthcare systems. Despite advances in treatment solutions over the last 30 years, improvements have not met the expectations for cardiac recovery and prognosis following heart attack. Current treatments are only partial solutions as they cannot regenerate the damaged heart tissue, and are thus unable to stop the progressive loss of heart function, low short- and medium-term life expectancy, and impoverished quality of life due to co-morbidities and/or frequent and continuous re-hospitalisations. Regenerative concepts, such as cellular therapies to regain cardiac function, once of the greatest hope for heart failure patients, have been recently discredited as they have been unable to show scientific proof of efficacy. Miracor, developed and clinically tested PiCSO, a breakthrough cardiac intervention triggering myocardial regeneration. Our therapy consists of a percutaneous right heart catheter intervention using proprietary software for feedback control that temporarily elevates the pressure in cardiac veins reactivating innate regeneration pathways. We have tested PiCSO in chronic HF patients (8 patients versus 22 controls) and demonstrated that 30 minutes of intervention changed the pattern of regenerative biomarkers in cardiac veins that resulted in significantly improved survival at 10 years follow up. Our patented technology (PiCSOHF ) is changing the market in HF, as no similar device is currently available. Our strategic goal is to become Europe´s leading reference in treating HF. After full technological, clinical and commercial development, PICSOHF profits will increase by €66M within 5 years after commercial launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PICSOHF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PICSOHF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More